Androgen Deprivation Therapy News and Research

RSS
Adamis' APC-300 inhibits growth of prostate cancer cells

Adamis' APC-300 inhibits growth of prostate cancer cells

Men with early-stage prostate cancer can benefit from short-term ADT, radiation therapy

Men with early-stage prostate cancer can benefit from short-term ADT, radiation therapy

GTx commences Capesaris Phase IIb trial in advanced prostate cancer

GTx commences Capesaris Phase IIb trial in advanced prostate cancer

Researchers reveal why anti-androgen therapy may fail in men with prostate cancer

Researchers reveal why anti-androgen therapy may fail in men with prostate cancer

Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

New targeted therapy may halt tumor growth in men with advanced prostate cancer

New targeted therapy may halt tumor growth in men with advanced prostate cancer

PCF funds 14 new Creativity Awards for advanced prostate cancer research

PCF funds 14 new Creativity Awards for advanced prostate cancer research

Obese men may face high risk of prostate cancer progression

Obese men may face high risk of prostate cancer progression

GTx reports net loss of $2.6 million for first quarter 2011

GTx reports net loss of $2.6 million for first quarter 2011

FDA approves new targeted therapy to treat men with advanced prostate cancer

FDA approves new targeted therapy to treat men with advanced prostate cancer

Majority of men on ADT after prostatectomy gain weight during first year of therapy

Majority of men on ADT after prostatectomy gain weight during first year of therapy

Ipsen, Gtx terminate collaboration for development and commercialization of toremifene

Ipsen, Gtx terminate collaboration for development and commercialization of toremifene

Sequencing of whole prostate cancer genomes - an historic development

Sequencing of whole prostate cancer genomes - an historic development

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

Expert discusses androgen deprivation therapy for prostate cancer

Expert discusses androgen deprivation therapy for prostate cancer

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

Androgen deprivation therapy may increase fracture risk in older men with localized prostate cancer: Research

Androgen deprivation therapy may increase fracture risk in older men with localized prostate cancer: Research

Long-term androgen deprivation therapy increases risk of fracture in older men with prostate cancer

Long-term androgen deprivation therapy increases risk of fracture in older men with prostate cancer

GTx third quarter net loss decreases to $8.6 million

GTx third quarter net loss decreases to $8.6 million

Medicare announces contracts for competitive bidding on equipment while docs worry about payment cuts

Medicare announces contracts for competitive bidding on equipment while docs worry about payment cuts